Next generation Sepsis pathogen diagnostics: Revolutionary device for rapid detection of Sepsis

49M patients are diagnosed with Sepsis and 11M die annually worldwide and costs over €30 billion to treat.

This is a senseless tragedy as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.SepTec is the groundbreaking, cost-effective technology required to provide the solution.

SepTec is a patent-pending in-vitro diagnostic device that screens blood for the diagnosis of sepsis infection, detecting and identifying pathogens within 15 minutes at very low concentrations (<10 CFU/ml) without the need complicated lab tests.

Preliminary health economics research shows that our rapid Sepsis infection diagnosis will result in patients receiving the correct treatment between 2 and 4.5 days earlier than in current protocols (resulting in a consequent 50% reduction in mortality rate), 25 times fewer patients receiving unnecessary antibiotics and a healthcare saving between €17-40m per 5m population.The global point of care market is expected to be valued €50.51bn by year 2026, (CAGR of 9.6%).

Within this market, the market for point-of-care tests (POCT) for infectious diseases (including sepsis) is €3.7bn annually and sepsis specific POC diagnostics testing market is expected to grow from €1bn by 2026.

To exploit this lucrative market opportunity, we must complete an innovation project to progress our highly promising results into a product suitable for a large-scale clinical validation, mass manufacturing and subsequently commercialization.